Investigators have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, a discovery that may lead to a new melanoma target or prompt new designs for treatment.
A new triple combination therapy has shown signs that it can more effectively control advanced melanoma that previous, dual-therapy combinations.
A phase 3 trial of brentuximab vedotin (BV) showed that adults with hard-to-treat Hodgkin lymphoma given BV after stem cell transplantation survived without the disease progression for twice as long as when a placebo was administered.
A new online tool uses a patient's molecular characteristics and provides feedback from an expert panel to help oncologists with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC).
Working with cells taken from children with a rare form of brain cancer, scientists have identified a genetic pathway that may spur cancer cell growth and resistance to anticancer treatment.
Researchers have identified a new therapeutic target for a particularly aggressive form of ovarian cancer, opening the door to effective targeted therapy development.
Researchers have developed a device that uses electric fields to drive chemotherapy drugs through the protective barrier of tissue and directly into pancreatic tumors, preventing their growth.
The therapeutic agent SapC-DOPS may have use in lung cancer treatment, according to a new study .
A recent study suggests that targeting a key enzyme and its associated metabolic programming could lead to a novel drug development for lung cancer treatment.
Women with stage 1 HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were unlikely to suffer cancer recurrence within 3 years of treatment.
Researchers believe they may have found a molecule-based approach to halting the destructive quality of the 3q26.2 amplicon, a frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.
An oral targeted agent has shown encouraging activity and limited side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML), according to research.
Patients with advanced leukemia, when treated with a new type of cancer therapy that blocks mutated IDH2 protein, showed dramatic results in a clinical trial.
A DNA vaccine targeting the breast cancer-associated antigen mammaglobin-A was proven safe and found to effectively elicit immune responses in women with metastatic breast cancer, according to a new study.
Researchers are now examining specific genetic mutations from a more Darwinian standpoint, to aid cancer treatment.
Personalized medicine is changing oncology nursing. This primer explains best practices for collecting and preparing biospecimens used to guide therapy.
Precision cancer treatment examines tumors on a genetic level with an aim to uncover the cause of the cancer's growth.
Glioblastoma multiforme (GBM) is one of the most lethal primary brain tumors, but new therapeutic strategies are being investigated.
Targeting BRAF V600E/K mutation-positive melanoma with dabrafenib in combination with trametinib achieves longer overall survival and impoved response rates, compared to treatment with vemurafenib alone.
Treatment with the drug crizotinib has been effective for stopping lung tumor growth driven by rearrangements of the ROS1 gene.
An analysis of circulating tumor cells (CTCs) in a pancreatic cancer model identified several different classes of CTCs and found unexpected factors that may prove to be future targets for improved treatment.
A targeted combination drug therapy has shown efficacy for metastatic melanoma, showing reduction in both mortality and disease progression.
About 14.5 million U.S. cancer survivors are alive today, but aging population and increasing obesity threaten progress.
Integrated approach to pinpoint genetic drivers of cancer uncovers viable targets for breast cancer therapySeptember 11, 2014
Researchers have developed a new integrated approach to identify the genetic drivers of cancer, uncovering eight genes necessary for cell proliferation in breast cancer.
EGFR mutations in circulating tumor DNA (ctDNA) can be used in place of tumor tissue in non-small cell lung cancer (NSCLC) diagnosticsSeptember 10, 2014
Epidermal growth factor receptor mutations found in ctDNA in the plasma of patients with advanced non-small cell lung cancer correlates well with the EGFR mutations from patient-matched tumor tissue DNA.
Researchers have found one key as to why certain glioblastomas are resistant to drug therapy, and the answer lies in a tumor's epigenetic signature.
New research suggests that an antidepressant medication, repurposed, could target a novel molecular pathway that causes an aggressive form of medulloblastoma.
Researchers have identified a gene that contributes to the development of several childhood cancers, research that could lead to new strategies for targeting certain childhood cancers at a molecular level.
- Vitamin D and prostate cancer: Higher intake improves active surveillance outcomes
- Triple combination of two targeted therapies + immunotherapy is more effective in advanced melanoma
- Muscle-building supplements may be associated with testicular cancer
- Promising drug target identified in medulloblastoma
- Physical activity associated with less chemo-induced peripheral neuropathy
- mHealth app assesses breast cancer risk and aids prevention
- Socioeconomic factors increase mortality after lung cancer surgery
- Half of older U.S. adults take aspirin as preventive medicine
- Cardiorespiratory fitness linked with decreased metabolic syndrome risk among smokers
- Adjuvant chemotherapy in non-small cell lung cancer: State-of-the-art
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|